---
layout: minimal-medicine
title: Ponatinib
---

# Ponatinib
### Generic Name
Ponatinib

### Usage

Ponatinib is a targeted therapy primarily used to treat chronic myeloid leukemia (CML) in adult patients.  Its specific application is in cases where the disease has become resistant to, or intolerable with, at least two other kinase inhibitors. This includes patients with chronic-phase (CP), accelerated-phase (AP), or blast-phase (BP) CML.  Ponatinib is also indicated for treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in situations where other kinase inhibitors aren't suitable.  A crucial use is in treating CML and Ph+ ALL that are positive for the T315I mutation, a mutation known for its resistance to many other CML treatments. Importantly, Ponatinib is *not* indicated for newly diagnosed CP-CML.


### Dosage

Ponatinib is administered orally as a tablet.  The standard starting dose for adults is 45 mg once daily. However, the dosage and duration of treatment vary significantly depending on the specific type and stage of leukemia, the patient's response to treatment, and the presence of side effects.

**Specific Dosage Considerations:**

* **CML (chronic phase, resistant or intolerant to at least two prior kinase inhibitors):** Initial dose is 45 mg daily.  The dose may be reduced to 15 mg daily if a specific blood test result (BCR-ABL1 IS ≤1%) is achieved.  The dose can be increased again to a previously tolerated level (30 or 45 mg) if the response is lost. Treatment continues until disease progression or unacceptable side effects.
* **CML (accelerated or blast phase, no other kinase inhibitors suitable):**  Initial dose is 45 mg daily.  A dose reduction may be considered in accelerated-phase patients who achieve a major cytogenetic response.
* **CML or Ph+ ALL (T315I-positive):** Initial dose is 45 mg daily.  Similar to chronic-phase CML, dose reduction to 15 mg may occur if BCR-ABL1 IS ≤1% is achieved, with potential re-escalation if needed.
* **Ph+ ALL (no other kinase inhibitors suitable):** Initial dose is 45 mg daily.


**Dosage Adjustments:**  Dose adjustments are frequently needed based on side effects, liver function, and potential interactions with other medications.  Significant reductions or treatment interruption might be necessary for issues such as low blood cell counts, high liver enzymes, serious cardiovascular events, or severe side effects.  Always consult a healthcare professional for dosage adjustments.  Consult your physician's prescribing information for detailed guidelines.


### Side Effects

Ponatinib carries a significant risk of side effects, some of which can be severe. The frequency of side effects varies widely among individuals. It is essential to report any new or worsening symptoms to your healthcare provider immediately.


**Common Side Effects (>10%):**

* Nervous system: Headache, dizziness, fatigue, anxiety, insomnia, peripheral neuropathy
* Cardiovascular: Hypertension, edema (swelling), arrhythmias, heart failure
* Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, decreased appetite
* Hematologic: Anemia, low white blood cell count, low platelet count
* Hepatic: Increased liver enzymes


**Serious but Less Common Side Effects (<10%, but potentially life-threatening):**

* Arterial occlusive events (stroke, heart attack, peripheral artery disease)
* Venous thromboembolic events (blood clots)
* Severe pancreatitis
* Severe hepatotoxicity (liver failure)
* Severe hypertension
* Serious cardiac arrhythmias
* Hemorrhage (bleeding)
* Reversible posterior leukoencephalopathy syndrome (RPLS)


### How it Works

Ponatinib is a tyrosine kinase inhibitor.  It works by blocking the activity of several enzymes, including BCR-ABL, which is a key enzyme involved in the development and progression of CML and Ph+ ALL. By inhibiting BCR-ABL and other related kinases, Ponatinib interferes with the uncontrolled growth and division of cancerous cells, helping to control the disease.  Its broad range of kinase inhibition accounts for its efficacy against various CML mutations, including the challenging T315I mutation.


### Precautions

* **Contraindications:** Ponatinib is contraindicated in individuals with hypersensitivity to the drug, uncontrolled cardiovascular risk factors (including hypertension), inadequate hydration, and uncorrected hyperuricemia.
* **Drug Interactions:**  Ponatinib's metabolism can be affected by other medications, particularly those that inhibit or induce the CYP3A4 enzyme. This can alter its concentration in the body, requiring close monitoring and potential dosage adjustments.  Consult your physician before starting any new medications while on Ponatinib.
* **Cardiovascular Risk:** Ponatinib is associated with a heightened risk of arterial occlusive events (e.g., stroke, heart attack), venous thromboembolic events, and heart failure. Careful monitoring of cardiovascular health is crucial. Patients with pre-existing cardiovascular disease should be carefully evaluated before starting Ponatinib.
* **Hepatotoxicity:** Liver damage is a potential risk. Regular monitoring of liver function is necessary.
* **Pregnancy and Breastfeeding:** Ponatinib is categorized as pregnancy category D, meaning it poses a risk to the fetus.  Effective contraception should be used during treatment and for a period afterward.  Breastfeeding should be avoided during treatment and for a specified time after discontinuation.
* **Other Precautions:**  Close monitoring for other side effects, including pancreatitis, neuropathy, and RPLS, is important.  Patients should be well-hydrated to minimize the risk of tumor lysis syndrome.  


### FAQs

* **Q: Can I drink grapefruit juice while taking Ponatinib?** A: No, grapefruit juice can increase Ponatinib levels in your blood, raising the risk of side effects. Avoid it.
* **Q: What should I do if I miss a dose?** A: Take the missed dose as soon as you remember, unless it's almost time for the next dose. Do not double the dose.
* **Q: How should I store Ponatinib?** A: Store Ponatinib tablets at room temperature, away from moisture and heat.
* **Q: When should I contact my doctor?** A: Contact your doctor immediately if you experience any new or worsening symptoms, especially those that are severe or concerning (e.g., chest pain, shortness of breath, severe headache, unusual bleeding or bruising, significant swelling).


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided here is not a substitute for the detailed prescribing information provided by the manufacturer.
